Z-AAT and M-AAT-Specific Binding Proteins for Point-of-Care Detection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current diagnostic methods for alpha-1 antitrypsin deficiency (AATD) are cumbersome, costly, and not well-suited for point-of-care testing, leading to underdiagnosis and misdiagnosis, which can mask the condition during acute-phase responses and other conditions.
Innovation Solution
Development of binding proteins, such as antibodies and antigen-binding fragments, that specifically target Z-AAT and M-AAT, enabling rapid and accurate detection of AATD through methods like lateral flow assays and ELISA, using solid supports with immobilized binding proteins to distinguish between different AAT variants.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If quantitative immunoprecipitation is used to measure serum AAT concentration, then the AAT level can be determined, but the diagnosis is insufficient because acute-phase responses and other conditions can mask partial AAT deficiency
Solution Approach 1:
The patent segments the AAT measurement into two distinct components: total AAT concentration measurement and AAT phenotype identification. By using specific antibodies that recognize different AAT variants (M, S, Z phenotypes), the method can distinguish between normal and deficient AAT levels regardless of acute-phase responses, thereby improving diagnostic reliability while maintaining measurement precision
Solution Approach 2:
The patent introduces phenotype-specific antibodies as intermediaries to detect AAT variants. These antibodies serve as mediators that specifically bind to different AAT phenotypes (M-AAT, S-AAT, Z-AAT), allowing the detection system to differentiate between normal and deficient states even when total AAT concentration is elevated due to acute-phase responses
2Measurement precision
If phenotypic analysis by IEF or agarose gel electrophoresis with immunofixation is performed, then AAT phenotype can be identified, but the procedure is cumbersome and requires special training and skills
Solution Approach 1:
The patent extracts the essential function of phenotype identification from the complex IEF and gel electrophoresis procedures. By using solid supports with immobilized phenotype-specific antibodies, the method isolates the key detection step from the cumbersome separation and analysis steps, maintaining accurate phenotype identification while dramatically simplifying the操作流程 and reducing the need for specialized training
Solution Approach 2:
The patent creates a simplified copy of the phenotyping function using solid support-based antibody binding. Instead of requiring complex electrophoresis setups and gel analysis, the invention replicates the phenotype detection capability through direct antibody-antigen binding on solid supports, which can be performed with standard laboratory equipment and minimal training
3Reliability
If genotyping methods are used for AATD diagnosis, then genetic confirmation can be obtained, but the method is expensive, requires special skills, and is not well suited for screening purposes
Solution Approach 1:
The patent creates a universal testing platform that can identify multiple AAT phenotypes (M, S, Z) and quantify AAT deficiency in a single assay. This multi-functional approach eliminates the need for separate genotyping procedures, providing both screening and diagnostic capabilities in one cost-effective test that can be performed efficiently in routine laboratories
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The binding proteins provide high specificity and sensitivity for detecting Z-AAT and M-AAT, allowing for efficient diagnosis of AATD, even in the presence of acute-phase responses, and facilitating point-of-care testing.
Implementation Method 1
binding proteins, such as antibodies and antigen-binding fragments, that specifically target Z-AAT and M-AAT, enabling rapid and accurate detection of AATD
Data Source
AI summary
Binding proteins that bind Z-alpha-1 antitrypsin (Z-AAT) and M-alpha-1 antitrypsin (M-AAT) are provided, as well as kits comprising the binding protein(s). The disclosure also provides a method for detecting Z-alpha-1 antitrypsin (Z-AAT) in a subject, a method of characterizing delivery of M-AAT to a subject suffering from AAT deficiency, and a method of detecting AAT deficiency in a subject.